Skip to main content
. Author manuscript; available in PMC: 2015 Feb 15.
Published in final edited form as: Cancer Res. 2014 Feb 10;74(4):979–1004. doi: 10.1158/0008-5472.CAN-13-2387

Figure 9.

Figure 9

In vivo noninvasive photoacoustic (PA) time-course coronal maximum amplitude projection (MAP) images of B16 melanomas using targeted [Nle4, D-Phe7]-α-melanocyte-stimulating hormone gold nanocages([Nle4, D-Phe7]-α-MSH-AuNCs) and non-targeted polyethylene glycol gold nanocages (PEG-AuNCs). (a,e) Photographs of nude mice transplanted with B16 melanomas before injection of (a) [Nle4,d-Phe7]-α-MSH- and (e) PEG-AuNCs. Time-course photoacoustic images of the B16 melanomas after intravenous injection with 100 μL of 10 nM (b−d) [Nle4,d-Phe7]-α-MSH- and (f−h) PEG-AuNCs via tail vein. The background vasculature images were obtained at 570 nm (ultrasonic frequency = 50 MHz), and the melanoma images were obtained at 778 nm (ultrasonic frequency = 10 MHz). Color schemes: red for blood vessels and yellow for the increase in PA amplitude. Reprinted with permission from Kim C et al. In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano. 2010;4(8):4559-64.). Copyright 2010 American Chemical Society.